5/22
11:48 am
pepg
We're Not Very Worried About PepGen's (NASDAQ:PEPG) Cash Burn Rate [Yahoo! Finance]
Low
Report
We're Not Very Worried About PepGen's (NASDAQ:PEPG) Cash Burn Rate [Yahoo! Finance]
5/20
02:08 pm
pepg
The Prognosis For PepGen [Seeking Alpha]
Low
Report
The Prognosis For PepGen [Seeking Alpha]
5/15
12:25 pm
pepg
PepGen Inc. (NASDAQ: PEPG) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock.
Low
Report
PepGen Inc. (NASDAQ: PEPG) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock.
5/15
10:30 am
pepg
PepGen Inc. (NASDAQ: PEPG) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
Low
Report
PepGen Inc. (NASDAQ: PEPG) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
5/14
04:16 pm
pepg
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
Low
Report
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
5/14
04:02 pm
pepg
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Low
Report
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
3/13
04:21 pm
pepg
PepGen to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
PepGen to Participate in Upcoming Investor Conferences [Yahoo! Finance]
3/13
04:05 pm
pepg
PepGen to Participate in Upcoming Investor Conferences
Low
Report
PepGen to Participate in Upcoming Investor Conferences
3/13
07:00 am
pepg
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
Low
Report
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
3/12
11:21 am
pepg
Can PepGen, Inc. (PEPG) Climb 48.62% to Reach the Level Wall Street Analysts Expect? [Yahoo! Finance]
Low
Report
Can PepGen, Inc. (PEPG) Climb 48.62% to Reach the Level Wall Street Analysts Expect? [Yahoo! Finance]
3/11
01:58 pm
pepg
PepGen, Inc. (PEPG) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]
Low
Report
PepGen, Inc. (PEPG) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]
3/7
08:25 am
pepg
PepGen Inc. (NASDAQ: PEPG) had its price target lowered by analysts at Wedbush from $21.00 to $20.00. They now have an "outperform" rating on the stock.
Medium
Report
PepGen Inc. (NASDAQ: PEPG) had its price target lowered by analysts at Wedbush from $21.00 to $20.00. They now have an "outperform" rating on the stock.
3/6
04:10 pm
pepg
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments [Yahoo! Finance]
Medium
Report
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments [Yahoo! Finance]
3/6
04:01 pm
pepg
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
Medium
Report
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
3/4
07:17 am
pepg
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy [Y
Medium
Report
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy [Y
3/4
07:00 am
pepg
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
Medium
Report
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy